Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:59 AM
Ignite Modification Date:
2025-12-25 @ 2:59 AM
NCT ID:
NCT02803333
Eligibility Criteria:
Inclusion Criteria:
* \>= 18 years of age
* Diagnosed with metastatic (stage 3b/4) non-small cell lung cancer (NSCLC)
* The total combined sample size must include at least 100 people who received one or more treatments of PD-1/PDL-1 inhibitor treatment (immunotherapy), and 50 patients who received an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI). Patients receiving any other treatments will be tracked for treatment outcomes, as well as to serve as comparison participants during data analyses of outcomes associated with PD-1/PDL-1 or EGFR-TKI).
* Consented separately to the Total Cancer Care (TCC) protocol
* Have access to the internet
* Willing to enroll in the free online health tracking and patient community "PatientsLikeMe"
Exclusion Criteria:
* Patients enrolled in Phase I clinical trial protocols
* Patients enrolled in Phase II, III or IV clinical trials involving blinded therapies (patients in open label trials will be eligible)
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02803333
Study Brief:
Protocol Section:
NCT02803333